CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions	Dec. 31, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 597.3	$ 322.6
Trade receivables, net	2,686.9	2,075.8
Inventories, net	1,256.6	889.2
Prepaid expenses and other current assets	966.4	650.8
Deferred tax assets, net	0.0	193.3
Total current assets	5,507.2	4,131.7
Property, plant and equipment, net	1,441.8	1,312.3
Intangible assets, net	23,083.0	11,277.9
Goodwill	18,552.8	9,361.4
Deferred tax assets, net	156.0	54.0
Other long-term assets, net	223.7	167.4
Total assets	48,964.5	26,304.7
Current liabilities:
Accounts payable	433.7	398.0
Accrued and other current liabilities	3,859.1	2,157.0
Acquisition-related contingent consideration	196.8	141.8
Current portion of long-term debt	823.0	0.9
Deferred tax liabilities, net	0.0	10.7
Total current liabilities	5,312.6	2,708.4
Acquisition-related contingent consideration	959.1	205.8
Long-term debt	30,265.4	15,228.0
Pension and other benefit liabilities	190.4	239.8
Liabilities for uncertain tax positions	120.2	102.6
Deferred tax liabilities, net	5,902.4	2,221.3
Other long-term liabilities	184.6	197.1
Total liabilities	$ 42,934.7	$ 20,903.0
Commitments and contingencies
Equity
Common shares, no par value, unlimited shares authorized, 342,926,531 and 334,402,964 issued and outstanding at December 31, 2015 and 2014, respectively	$ 9,897.4	$ 8,349.2
Additional paid-in capital	304.9	243.9
Accumulated deficit	(2,749.7)	(2,397.8)
Accumulated other comprehensive loss	(1,541.6)	(915.9)
Total Valeant Pharmaceuticals International, Inc. shareholders’ equity	5,911.0	5,279.4
Noncontrolling interest	118.8	122.3
Total equity	6,029.8	5,401.7
Total liabilities and equity	$ 48,964.5	$ 26,304.7